Sign inJoin
Company / Finance

Abbott Laboratories

ABT · NYSE

Abbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.

FollowAdd to WatchlistAsk Question
NYSEABTCoverage BootstrapHealth CareMedical DevicesDiagnostics
Latest ReportMay 13, 2026Abbott (ABT): the diabetes-device machine now carrying a $20.6B cancer-diagnostics betView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
DiagnosticsCoverage Bootstrap
Clear tags
MatchAny tagAll tags
Latest Thesis

Abbott (ABT): the diabetes-device machine now carrying a $20.6B cancer-diagnostics bet

Abbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Abbott Laboratories(ABT): the diabetes-device machine now carrying a $20.6B cancer-May 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Abbott (ABT): the diabetes-device machine now carrying a $20.6B cancer-diagnostics betAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.NYSEMay 13, 2026Research reportReadSlides